Export

ATC codes: A01AB17
EMLc
Indication
Other specified prophylactic measures ICD11 code: QC96.Y
INN
Metronidazole
Medicine type
Chemical agent
Antibiotic groups
List type
Core
Formulations
Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Local > Rectal > Suppository: 500 mg suppository (EML) ; 1 g suppository (EML)
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
EML status history
First added in 2019 (TRS 1021)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Expert Committee recommendation
The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of a new strength dispersible tablet formulation (250 mg + 62.5 mg) of amoxicillin + clavulanic acid to the EMLc. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended that the range of strengths of metronidazole tablets be replaced with reference to specific strengths on the EML and EMLc.
EML recommendations: Other specified prophylactic measures
First choice
Second choice
surgical prophylaxis